VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients.

被引：0
|
作者：
Colado, Enrique [1 ]
Mateos, Maria-Victoria [1 ]
Moreno, Maria-Jose
Dearriba, Felipe
de la Rubia, Javier
Lahuerta, Juan Jose [2 ]
Iniesta, Pastora
Viguria, Maria Cruz
Gonzalez, Ana Pilar
Garcia-Sanz, Ramon [1 ]
Olazabal, Juan [1 ]
Miguel, Jesus F. San [1 ]
机构：
[1] Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain
[2] Hosp 12 Octubre, E-28041 Madrid, Spain
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1265 / 1266
页数：2
相关论文
共 50 条
  • [1] VAMP/THACYDEX: VELCADE8 (BORTEZOMIB) ADRIAMYCIN, MELPHALAN AND PREDNISONE ALTERNATING WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETASONE AS A SALVAGE REGIMEN IN RELAPSED MULTIPLE MYELOMA PATIENTS: A SPANISH MYELOMA GROUP (GEM/PETHEMA) STUDY
    Colado, E.
    Mateos, M. V.
    De Arriba, M. J. Moreno F.
    De la Rubia, J.
    Iniesta, P.
    Viguria, M. C.
    Garcia-Sanz, R.
    Olazabal, J.
    San Miguel, J. F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 262 - 262
  • [2] Alternating VAMP/ThaCyDex: An Effective Salvage Regimen in Relapsed Multiple Myeloma Patients
    Colado, E.
    Garcia-Sanz, R.
    Olazabal, J.
    Martin-Sanchez, J.
    Miguel, San
    Mateos, M. V.
    Moreno, M. J.
    de Arriba, F.
    de la Rubia, J.
    Lahuerta, J. J.
    Iniesta, P.
    Gonzalez, A. P.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S72 - S73
  • [3] Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
    Palumbo, Antonio
    Ambrosini, Maria Teresa
    Benevolo, Giulia
    Pregno, Patrizia
    Pescosta, Norbert
    Callea, Vincenzo
    Cangialosi, Clotilde
    Caravita, Tommaso
    Morabito, Fortunato
    Musto, Pellegrino
    Bringhen, Sara
    Falco, Patrizia
    Avonto, Ilaria
    Cavallo, Federica
    Boccadoro, Mario
    BLOOD, 2007, 109 (07) : 2767 - 2772
  • [4] BORTEZOMIB (VELCADE)-MELPHALAN-PREDNISONE (VMP) VERSUS VELCADE-THALIDOMIDE-PREDNISONE (VTP) IN ELDERLY UNTREATED MULTIPLE MYELOMA (MM) PATIENTS
    Mateos, M. V.
    Oriol, A.
    Martinez, J.
    Cibeira, M. T.
    de Paz, R.
    Terol, M. J.
    Garcia-Larana, J.
    Bengoechea, E.
    Martinez, R.
    Martin, A.
    de Arriba, F.
    Palomera, L.
    Hernandez, J. M.
    Bello, J. L.
    Martin, M. L.
    Gonzalez, Y.
    Lahuerta, J. J.
    Blade, J.
    San Miguel, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 190 - 190
  • [5] Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma
    Chanan-Khan, A
    Miller, KC
    LEUKEMIA & LYMPHOMA, 2005, 46 (07) : 1103 - 1104
  • [6] Bortezomib (Velcade™) plus Adriamycin™ plus thalidomide plus dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM)
    Hollmig, K
    Stover, J
    Talamo, G
    Fassas, A
    Lee, CK
    Anaissie, E
    Tricot, G
    Barlogie, B
    BLOOD, 2004, 104 (11) : 659A - 659A
  • [7] Factors predictive of outcome in relapsed, refractory multiple myeloma patients treated with bortezomib, melphalan, prednisone, and thalidomide (VMPT)
    Palumbo, A. P.
    Ambrosini, M. T.
    Benevolo, G.
    Pescosta, N.
    Callea, V.
    Cangialosi, C.
    Caravita, T.
    Morabito, F.
    Gay, F.
    Boccadoro, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade-Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?
    Mateos, Maria-Victoria
    Oriol, Albert
    Martinez, Joaquin
    Cibeira, M. Teresa
    de Paz, Raquel
    Terol, M. Jose
    Garcia-Larana, Jose
    Bengoechea, Enrique
    Martinez, Rafael
    Martin, Alejandro
    de Arriba, Felipe
    Palomera, Luis
    Hernandez, Jose
    Bello, Jose-Luis
    Martin, Maria-Luisa
    Gonazlez, Yolanda
    Blade, Joan
    Jose Lahuerta, Juan
    San Miguel, J. F.
    BLOOD, 2008, 112 (11) : 243 - 243
  • [9] Intermediate dose melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) conditioning therapy and ASCT in relapsed multiple myeloma patients: A single center experience
    Scalzulli, Polito Rosario
    Valvano, Maria Rosa
    Bodenizza, Carlo C.
    Carella, Angelo Michele
    Dell'Olio, Matteo M.
    Falcone, Antonietta A. P.
    Greco, Michele Mario
    La Sala, Antonio A.
    Mantuano, Francesco F. S.
    Melillo, Lorella L.
    Merla, Emanuela E.
    Nobile, Michele M.
    Sanpaolo, G. Sanpaolo
    Cascavilla, Nicola N.
    BLOOD, 2007, 110 (11) : 361B - 361B
  • [10] Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Davide
    Ria, Roberto
    Offidani, Massimo
    Patriarca, Francesca
    Nozzoli, Chiara
    Levi, Anna
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Callea, Vincenzo
    Olivero, Barbara
    Morabito, Fortunato
    Grasso, Mariella
    Marasca, Roberto
    Rizzo, Manuela
    Falcone, Antonietta Pia
    Gottardi, Daniela
    Montefusco, Vittorio
    Musolino, Caterina
    Zambello, Renato
    Cangialosi, Clotilde
    Pietrantuono, Giuseppe
    Magarotto, Valeria
    Petrucci, Maria Teresa
    Musto, Pellegrino
    Ciccone, Giovannino
    Di Raimondo, Francesco
    Gaidano, Gianluca
    Boccadoro, Mario
    BLOOD, 2009, 114 (22) : 58 - 58
12345